Listen to our Editorial Board reflecting on their highlights from the ADA scientific sessions, with discussion on the VERTIS-CV trial, diets for diabetes, insulin icodec and more (34:17).
A novel insulin that can be given as a once-weekly injection has achieved promising results in a randomized phase 2 trial involving people with type 2 diabetes.
Icosapent ethyl reduces the risk for first and total cardiovascular events in statin-treated patients with diabetes, suggests a subgroup analysis of the REDUCE-IT trial.
Doctors are faster to initiate pharmacologic type 2 diabetes treatment in people from ethnic minorities than in White people but are then slower to intensify their treatment when needed, show data from the UK.
A study shows marked variations in cardiovascular risk burden according to age, sex, and ethnicity at the point of type 2 diabetes diagnosis, with implications for both diabetes prevention and cardiovascular risk management.
A major genetic analysis sheds light on the similarities and differences in type 2 diabetes pathogenesis between people of East Asian and European origin.
People who meet the criteria for prediabetes during the 3 years before a type 2 diabetes diagnosis have a higher burden of vascular disease than those who do not, research shows.
US primary care physician Neil Skolnik discusses the role of oral semaglutide in the care of people with type 2 diabetes and outlines key considerations for its use (12:26) [Listen now]
A large observational study reveals a strong link between reduced kidney function and increased incidence of hypoglycemia in adults with diabetes in routine clinical practice.
People with type 2 diabetes who are treated with metformin prior to undergoing major surgical interventions may have better postoperative outcomes than those without exposure to the drug, researchers report.
The results of a small randomized trial suggest exercise is more helpful than diet for combating early cardiac dysfunction associated with type 2 diabetes, although both may be beneficial.
Treatment with dapagliflozin is associated with a significant reduction in the risk for heart failure worsening or cardiovascular death in people with heart failure and reduced ejection fraction regardless of whether or not they have diabetes, shows an exploratory analysis of DAPA-HF trial data.
Older adults with type 2 diabetes often receive diabetes medication adjustments at hospital discharge that may be of little or no benefit, study results suggest.
Adding liraglutide 3.0 mg to intensive behavioral therapy increases weight loss in overweight or obese people with insulin-treated type 2 diabetes, results of the phase 3 SCALE Insulin trial show.
More than half of people with coronary artery disease have impaired glucose tolerance, yet many are unaware of this or are undertreated despite knowledge of their condition, results of the EUROASPIRE V survey show.
The risk associated with a family history of type 2 diabetes is highest for people whose near relatives were diagnosed with the condition at a young age, show registry data.
Optimal glycemic control during the first years after a latent autoimmune diabetes of adulthood diagnosis could prevent people’s microvascular complication risk from equaling that seen in those with type 2 diabetes, shows an analysis of the UKPDS.
US primary care physician Neil Skolnik discusses the role of oral semaglutide in the care of people with type 2 diabetes and outlines key considerations for its use (12:26).
Diagnosis and management of prediabetes: a consensus of GCC countries
Guidance based on outcomes of an advisory board of diabetes experts, for healthcare professionals addressing the diagnosis and treatment of prediabetes.
This interactive roadmap is intended for healthcare professionals practicing in Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, and Oman.
Funding for this roadmap was provided by Merck Serono Middle East FZ-LLC
These slide sets summarize the results of randomized controlled trials investigating the use of flash glucose-sensing technology in patients with diabetes.
Funded by an educational grant from Abbott Diabetes Care
An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.
A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.
Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.
Themed collections
Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.
Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.
